Eddie Sullivan is the founder of SAB Biotherapeutics. Latest round: Series A. SAB Biotherapeutics raised $22 million in a Series A-2 round in 2018.
Eddie Sullivan is the co-founder, President, and former CEO of SAB Biotherapeutics, a clinical-stage biopharmaceutical company. The company focuses on developing human immunotherapies for various diseases, including infectious diseases, autoimmune disorders, and cancer, using its unique DiversitAb™ platform to produce fully human immunoglobulins. SAB Biotherapeutics raised $22 million in a Series A-2 round in 2018. Sullivan has over 30 years of experience in biopharma leadership, having raised over $800 million in capital for biopharmaceutical platform technologies.
Full founder directory · Investor directory · Company funding database · Fundraising library